Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 3
2(40.0%)
5Total
Phase 2(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00844662Phase 3Terminated

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

Role: lead

NCT00841126Phase 3Terminated

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

Role: lead

NCT00358722Phase 2Terminated

An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate

Role: lead

NCT00436683Phase 2Completed

Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia

Role: lead

NCT00317694Phase 2Completed

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

Role: lead

All 5 trials loaded